Directory of funded grants

Filter by

552 results found

Selective knockdown of misfolded SOD1 as a therapy for amyotrophic lateral sclerosis

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Arthur J. Hudson Translational Team Grant

  • Province

    Manitoba

  • Start Date

    2015

  • Total Grant Amount

    $1,600,250

  • Health Canada Contribution

    $800,125

Project Overview

In some cases of ALS, it is clear that specific inherited genetic changes (called mutations) can not only cause the disease, but can do so by creating a protein (the end product of genes that actually does a function in our cells) that has an abnormal, toxic function resulting in…

Project Complete

See the project and researchers

The role of peripheral inflammation in ALS: an exploratory study

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    British Columbia

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

It has been more than a decade since scientists proved that ALS is not simply a disease of motor neurons, but that other cells in the neighbourhood around them could play an active role in the disease process. A series of intricate experiments demonstrated that genetically ‘turning off’ ALS in…

Project Complete

See the project and researchers

Misfolded SOD1 in ALS pathogenesis

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

The first genetic cause of ALS to be discovered (in 1993) encoded a mutation in protein called superoxide dismutase 1 (SOD1). Decades later, it is largely agreed upon that the abnormal shape (called misfolding) of SOD1 mutants is at the root of toxicity in some forms of ALS. Traditionally, misfolded…

Project Complete

See the project and researchers

Study of the impact of glycation on ALS using an in vitro tissue-engineered model of spinal cord

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Tissue engineering is a process that was originally designed and continues to be used for growing cells outside the body, turning them into functional tissues and organs, and applying them for clinical use. Skin grafting and developing new organs for transplant are examples of how tissue engineering are used as…

Project Complete

See the project and researchers

RGNEF modulates protein misfolding in ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Discoveries made in Canada by the lab of Dr. Michael Strong over the past few years have implicated a protein called Rho guanidine nucleotide exchange factor (RGNEF) both pathologically and genetically in causing ALS. Further study demonstrated that RGNEF could play a role in the abnormal shape (misfolding) and toxicity…

Project Complete

See the project and researchers